Coopération entre mutation somatique et variant génétique de susceptibilité dans le sarcome d’Ewing

Thomas G.P. Grünewald; Pascale Gilardi-Hebenstreit; Patrick Charnay; Olivier Delattre

doi:10.1051/medsci/20163204004

Home

All issues

Volume 32 / No 4 (Avril 2016)

Med Sci (Paris), 32 4 (2016) 323-326

References

Free Access

Issue		Med Sci (Paris) Volume 32, Number 4, Avril 2016


Page(s)		323 - 326
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20163204004
Published online		02 May 2016

Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013 ; 499 : 214–218. [CrossRef] [PubMed] [Google Scholar]
Grünewald TGP, Bernard V, Gilardi-Hebenstreit P, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet 2015 ; 47 : 1073–1078. [CrossRef] [PubMed] [Google Scholar]
Lawlor ER, Sorensen PH. Twenty years on : what do we really know about Ewing sarcoma and what is the path forward? Crit Rev Oncog 2015 ; 20 : 155–171. [CrossRef] [PubMed] [Google Scholar]
Tirode F, Laud-Duval K, Delattre O. Origine cellulaire des tumeurs d’Ewing : un coin de voile est levé. Med Sci (Paris) 2008 ; 24 : 248–251. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
Guillon N, Tirode F, Boeva V, et al. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009 ; 4 : e4932. [CrossRef] [PubMed] [Google Scholar]
Riggi N, Knoechel B, Gillespie SM, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 2014 ; 26 : 668–681. [CrossRef] [PubMed] [Google Scholar]
Postel-Vinay S, Véron AS, Tirode F, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012 ; 44 : 323–327. [CrossRef] [PubMed] [Google Scholar]
Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994 ; 371 : 796–799. [CrossRef] [PubMed] [Google Scholar]
Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, et al. Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 2006 ; 26 : 9771–9779. [CrossRef] [PubMed] [Google Scholar]
Menjak IB, Gupta A, Grinman MN. Delayed diagnosis of metastatic Ewing sarcoma masked by Charcot-Marie-Tooth disease. J Adolesc Young Adult Oncol 2013 ; 2 : 175–178. [CrossRef] [PubMed] [Google Scholar]
Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012 ; 337 : 1190–1195. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013 ; 499 : 214–218. [CrossRef] [PubMed] [Google Scholar]

[2] Grünewald TGP, Bernard V, Gilardi-Hebenstreit P, et al. Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. Nat Genet 2015 ; 47 : 1073–1078. [CrossRef] [PubMed] [Google Scholar]

[3] Lawlor ER, Sorensen PH. Twenty years on : what do we really know about Ewing sarcoma and what is the path forward? Crit Rev Oncog 2015 ; 20 : 155–171. [CrossRef] [PubMed] [Google Scholar]

[4] Tirode F, Laud-Duval K, Delattre O. Origine cellulaire des tumeurs d’Ewing : un coin de voile est levé. Med Sci (Paris) 2008 ; 24 : 248–251. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

[5] Guillon N, Tirode F, Boeva V, et al. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function. PLoS One 2009 ; 4 : e4932. [CrossRef] [PubMed] [Google Scholar]

[6] Riggi N, Knoechel B, Gillespie SM, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell 2014 ; 26 : 668–681. [CrossRef] [PubMed] [Google Scholar]

[7] Postel-Vinay S, Véron AS, Tirode F, et al. Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet 2012 ; 44 : 323–327. [CrossRef] [PubMed] [Google Scholar]

[8] Topilko P, Schneider-Maunoury S, Levi G, et al. Krox-20 controls myelination in the peripheral nervous system. Nature 1994 ; 371 : 796–799. [CrossRef] [PubMed] [Google Scholar]

[9] Decker L, Desmarquet-Trin-Dinh C, Taillebourg E, et al. Peripheral myelin maintenance is a dynamic process requiring constant Krox20 expression. J Neurosci 2006 ; 26 : 9771–9779. [CrossRef] [PubMed] [Google Scholar]

[10] Menjak IB, Gupta A, Grinman MN. Delayed diagnosis of metastatic Ewing sarcoma masked by Charcot-Marie-Tooth disease. J Adolesc Young Adult Oncol 2013 ; 2 : 175–178. [CrossRef] [PubMed] [Google Scholar]

[11] Maurano MT, Humbert R, Rynes E, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012 ; 337 : 1190–1195. [CrossRef] [PubMed] [Google Scholar]